



Quantitative Flow Ratio (QFR®)

**An image-based assessment
of coronary physiology**


**Johan HC Reiber, PhD
CSO**

**Medis medical imaging systems bv
Leiden, The Netherlands**

Ischemic heart disease


- Ischaemic Heart Disease (IHD) is the world's leading cause of mortality, and responsible for the death of 1.8 million Europeans each year.
- In IHD, plaque formation narrows the blood vessels of the heart, reducing the functional capacity of a coronary artery to perfuse the heart muscle.
- Current clinical guidelines demand physiologic assessment of coronary plaques (i.e. effect of narrowings on the perfusion of the heart muscle) during a cardiac catheterization to guide treatment decisions (medical treatment vs. stent placement).

Cardiac catheterization




Cardiac catheterization is a procedure used to diagnose and treat certain **cardiovascular** conditions. During **cardiac catheterization**, a long thin tube called a **catheter** is inserted in an artery or vein in your groin, neck or arm and threaded through your blood vessels to your **heart**.

Movie catheterization



To treat or not to treat?



Anatomy: diameter stenosis =
53%

vs.

Physiology: FFR = 0.85

Quantitative Coronary Angiography (QCA)

Our first QCA was developed in 1979

Fractional Flow Reserve (FFR)

- **FFR** is a quantitative measurement of the functional severity of the coronary stenosis

$$\text{FFR} = \frac{\text{Distal Coronary Pressure (Pd)}}{\text{Proximal Coronary Pressure (Pa)}}$$

During maximum hyperemia



Intervention Yes/No is typically based on $\text{FFR} \leq$ or > 0.80

FFR was developed by Prof Nico Pijls et. al. in the 1995's

2018 ESC/EACTS Guidelines on myocardial revascularization

Recommendations	Class ^a	Level ^b
When evidence of ischaemia is not available, FFR or iwFR are recommended to assess the haemodynamic relevance of intermediate-grade stenosis. ^{15,17,18,39}	I	A
FFR-guided PCI should be considered in patients with multivessel disease undergoing PCI. ^{29,31}	IIa	B
IVUS should be considered to assess the severity of unprotected left main lesions. ^{35–37}	IIa	B

European Heart Journal, September 2018

Limitations pressure wire




- Invasive
- Need for adenosine:
 - Discomfort; Arrhythmia
- Time consuming
- Pullback device not available
- Suboptimal FFR measurements occur in about 1/3 of tracings; JACC Interv 2017; 10:1392; FFR is not reproducible
- For bifurcations, wire in both main vessel and sidebranch
- Expensive for operator or hospital
- Worldwide acceptance 7-10% max





QFR

(Quantitative Flow Ratio = Medis' QCA derived FFR)



3D model reconstructed from 2 angiographic projections with angles $\geq 25^\circ$ apart, acquired by monoplane or biplane systems.

QFR = 0.87

FFR = 0.85

Patient-specific **volumetric flow rate** (at hyperaemia) calculated using the combination of contrast bolus front **frame count** and **3D QCA**;

In-procedure time: < 5 min

Based on EuroPCR presentation by Niels Holm, MD
Aarhus University Hospital, Skejby • Denmark

Medis QFR: One-stop shop? V 1



Medis **First Clinical Trial Publications**

JACC: CARDIOVASCULAR INTERVENTIONS
© 2014 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION
PUBLISHED BY ELSEVIER INC.

VOL. 7, NO. 7, 2
ISSN 1936-8798/530
<http://dx.doi.org/10.1016/j.jcin.2014.03>

JACC: CARDIOVASCULAR INTERVENTIONS
© 2014 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION
PUBLISHED BY ELSEVIER INC.

Fractional Flow Reserve Calculation From 3-Dimensional Quantitative Coronary Angiography and TIMI Frame Count

**A Fast Computer Model to Quantify the Functional Significance
of Moderately Obstructed Coronary Arteries**

Shengxian Tu, PhD,* Emanuele Barbato, MD, PhD,† Zsolt Kőszegi, MD, PhD,‡
Junqing Yang, MD,§ Zhonghua Sun, MD,|| Niels R. Holm, MD,¶ Balázs Tar, MD,‡
Yingguang Li, MSc,* Dan Rusinaru, MD,† William Wijns, MD, PhD,†
Johan H.C. Reiber, PhD*

*Leiden, the Netherlands; Aalst, Belgium; Nyiregybaza, Hungary; Guangzhou and Tianjin, China; and
Skejby, Denmark*

EDITORIAL COMMENT

Fractional Flow Reserve From 3-Dimensional Quantitative Coronary Angiography

Fresh Light Through an Old Window*

Alexandra J. Lansky, MD, Cody Pietras, BSc

New Haven, Connecticut

In this issue of *JACC: Cardiovascular Interventions*, Tu et al. (1) report on an initial validation study for a less-invasive approach to derive fractional flow reserve (FFR) based on the coronary angiogram. The investigators should be congratulated on developing an innovative means to expand the diagnostic value of angiography by including physiological ischemic assessment, potentially broadening access FFR data to every patient undergoing cardiac catheterization.



FAVOR II Pilot Trial

- Finalized recruitment and analyses of 73 patients in multi-center setting for optimizing algorithms;
- Tested 3 different scenarios:
 - 1) with adenosine;
 - 2) without adenosine; and
 - 3) fixed flow velocity;
- FAVOR II confirmed results of FAVOR I;
- **Major result: Image-based physiology feasible: no wire, no adenosine**
- Manuscript published JACC Interv;2016;9: 2024-35
- Available as imaging vendor independent commercial product July 1, 2016;

JACC: CARDIOVASCULAR INTERVENTIONS

© 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION

PUBLISHED BY ELSEVIER

VOL. 9, NO. 19, 2016

ISSN 1936-8798/\$36.00

<http://dx.doi.org/10.1016/j.jcin.2016.07.013>

Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography



The International Multicenter FAVOR Pilot Study

Shengxian Tu, PhD,^a Jelmer Westra, MS,^b Junqing Yang, MD,^c Clemens von Birgelen, MD, PhD,^d Angela Ferrara, MD,^e Mariano Pellicano, MD,^{e,f} Holger Nef, MD,^g Matteo Tebaldi, MD,^h Yoshinobu Murasato, MD, PhD,ⁱ Alexandra Lansky, MD, PhD,^j Emanuele Barbato, MD, PhD,^{e,f} Liefke C. van der Heijden, MD,^d Johan H.C. Reiber, PhD,^k Niels R. Holm, MD,^b William Wijns, MD, PhD,^{e,l}
on behalf of the FAVOR Pilot Trial Study Group



FAVOR II EU/JP

Diagnostic Accuracy of On-line Quantitative Flow Ratio Functional Assessment by Virtual Online Reconstruction

An academic international multicenter trial by Aarhus University Hospital,
Denmark

Purpose

- To evaluate the feasibility and diagnostic precision of QFR during CAG with FFR as gold standard.


Hypothesis

- 1) QFR can be assessed during the cardiac catheterization procedure for stenosis interrogated by FFR
- 2) QFR is accurate with FFR as gold standard

Design


- Prospective, observational, multicenter study with inclusion of 300 patients.

Primary endpoint




Comparisons by McNemar's test

Results – QFR vs. 2D-QCA with FFR as reference



Results – Time to QFR and FFR



FAVOR II China

Diagnostic Accuracy of the Angiographic Quantitative Flow Ratio in Patients With Coronary Artery Disease

Bo Xu, MBBS

On behalf of the FAVOR II China Investigators

Quantitative Flow Ratio (QFR)

Standard Angiogram



Data Transmission System




Two image runs with
angle difference $\geq 25^\circ$




AngioPlus System


3D Reconstruction



Modified Frame Count




QFR



Without Inducing Hyperemia


Receiver Operating Curves for the Discrimination of Functionally Significant Stenosis (Online Analysis)





QFR can be assessed with most modern Philips, Siemens, GE and Canon X-ray systems

QFR fits very well in the clinical workflow



Slide 22

DGM21


Slide is good but requires simplifications. GE suggestions: 1) Ask Dr Maillard for testimonial about time saved due to QFR. Set up small study to show the time for patient study without physiology; the time for patient study with FFR vs the QFR analysis needed where the QFR analysis is performed while the other diagnostic angiograms are being acquired

Daniel Garcia Miranda; 28-04-19



QFR fits very well in the clinical workflow

QFR pre- (, during) and post-PCI



Slide 23

DGM22

GE feedback: More emphasis on the proof of success, second QFR is actually a test of success which failed.
For GE sepecific: in the middle it should become PCI assist.

If you use no FFR or QFR you take some risk
If use FFR it takes longer


Too many things on the slide: does not give the impression that QFR will reduce the work flow
Daniel Garcia Miranda; 29-04-19

Peripheral Hospitals can perform QFR at the point of care

Peripheral Hospital


Diagnostic Cath Lab

Scenario 1:




Patient goes home
(with medication)

Scenario 2:





Transfer of
QFR results
to other
hospital

PCI Center




PCI Cath Lab

PCI procedure



**Proof of
PCI success**

Example QFR-guided PCI



Courtesy Dr Liew – Queen Elizabeth Hospital – Kota Kinabalu



Scientific evidence supporting QFR[®]

QFR has an excellent correlation with FFR and good clinical accuracy

Scientific evidence since 2014:


- 50+ peer reviewed papers in international literature, incl. > 10.000 patients
- 70+ congress abstracts
- 15+ live case demonstrations worldwide
- All data very consistent and robust

QFR meta-analysis of four major multi-center QFR clinical trials¹⁻⁴, conducted by Aarhus University, Denmark, shows:



- Good correlation to FFR, no systemic differences
- Good clinical diagnostic accuracy

1. Westra J et al. Circ Cardiovasc Imaging 2018; 11.
2. Tu S et al. J Am Coll Cardiol Interv 2016; 9: 2024-35.
3. Westra J et al. J Am Heart Assoc 2018; 7.
4. Xu B et al. J Am Coll Cardiol 2017; 70: 3077-87.




QFR Next steps: RCTs

FAVOR III Europe - Japan

- QFR vs FFR
- Non-inferiority study

FAVOR III China

- QFR vs present practice
- Superiority study



Design overview

- Stable angina pectoris or evaluation of secondary stenosis
- Coronary stenosis of 40-90% by visual estimate



1:1 randomization of 2000 patients



QFR guiding



FFR guiding



Primary endpoint: One year PoCE for non-inferiority

Two-year follow-up

Only clinical follow-up

- QFR is market cleared in the following countries:

Country	Clarence	Description
European Union	YES	(CE)
Iceland	YES	(CE)
Liechtenstein	YES	(CE)
Norway	YES	(CE)
Switzerland	YES	(CE)
Turkey	YES	(CE)
Canada	YES	(CMDR)
Australia	YES	(TGA)
Brazil	YES	(ANVISA)
China*	YES	(CFDA)
Singapore	YES	(HAS)
Indonesia	YES	(KKRI)
South Africa	YES	(SAHPRA)
South Korea	Pending	(MFDS)
Japan	Pending	(PMDA)
USA	YES	(FDA)



Conclusions

- Fast computation of FFR from coronary angiography (QFR), acquired with or without pharmacological hyperemia-induction, is feasible.
- Contrast-flow QFR (cQFR) based on conventional diagnostic coronary angiography provides results similar to QFR based on hyperemic conditions, and is superior to fixed-flow QFR.
- The favorable results of cQFR bears the potential of a wider adoption of FFR-based lesion assessment, as cQFR might reduce procedure time, risk, and costs (no need to use pressure wire, and no need to induce maximal hyperemia) .
- The use of QFR is not without a stiff learning curve, which requires that users be certified by Medis before being able to start.
- Current indications: Patients with stable angina;
- Under investigations: MI, bifurcation lesions, lengthy diffuse disease, etc.
- CE certification April 2017
- FDA 510(k) approval May 2019

- **For patients:**
 - No adenosine with side-effects
 - No extra radiation
 - Less chances on complications due to wire insertion
- **For (interventional) cardiologist:**
 - Applicable in diagnostic cases;
 - Applicable pre-, during-, and post-PCI
 - Applicable in all coronary vessels without repeat insertions of wire
- **For hospitals:**
 - Cost-effective

Hurdles

■ Outcome study

- Despite all the extensive clinical global evidence, the technology will not appear in a Guideline until an Outcome Study with non-inferiority relative to the standard pressure wire has been performed (> 2000 ptns); Ongoing FAVOR III

■ Reimbursement by insurance companies

- In many countries very complex, lengthy, expensive and unpredictable process
- Even if there is no reimbursement, to change the healthcare system to go from one established technique to a newer one is difficult
- In the Netherlands “van kastje naar de muur”
- UK has a very clear and professional approach with the NICE Guidelines

■ Significant investment to roll out the new technology worldwide

- The use of QFR is not without a learning curve, which requires that users be certified by Medis before they are allowed to use clinically;
- This is not scalable: AI needed to further simplify and automate the process.

 **Medis** **Thank you for your attention**

